Therapy with Lung Carcinoma

A new therapy in the advanced stage with Lung Carcinomas, in whose development Viennese Onkologen cooperated, extends the survival period of the patients and restrains the illness. On the occasion of the European congress of cancer in Berlin, the British medicine technical periodical published on Sunday “The Lancet on-line results of a large-scale Studie.”

As reported, per year more than one million humans die world-wide at a lung carcinoma. 87% of it at a non-small-cellular lung carcinoma. With 40% of the patients the illness is already at the time of the diagnosis far fortgeschritten, that wrote specialized journal normally receives such patients four or six cycles of a combination chemotherapy, with which one of the substances is Cisplatin.

There was so far the treatment guideline if the illness comes to the stop according to which one should wait, until the illness progresses again, in order to then use means of the second and third choice.

Chandra Belani fom Pennsylvania State University together with the Co authors of 83 centers in 20 states tested an alternative to this strategy. They gave 663 patients in the stage to IIIb or Stage IV of a non-small-cellular lung carcinoma, with which the illness with the first chemotherapy had been stopped, either the substance Pemetrexed (441 test persons) or a placebo (222 test persons). Otherwise the patients received at present optimal Begleitbehandlung.

In Austria were at the study Thomas Brodowicz (university clinic for internal medicine I/MedUni Wien/AKH Vienna) as well as hospital boss Christoph Zielilnski taken part. The therapy took place in cycles every three weeks. Pemetrexed is an analogue of the Folsäure and intervenes in cells in the synthesis of the hereditary property components (DNA, RNA). The Wissenschafter obtained good results with the new preservation therapy: Thus the time interval up to progressing the illness increased of on the average 2.6 to 4,3 Monate.

Die average duration of survival could of 10,6 to 13.4 months be increased under therapy of Pemetrexed. The additional therapy was relatively well stood of the patients. 5% thereby of the treated ones fallow it because of side effects off. In the group of placebos it was a per cent sound the authors stands thereby also for patients with an inoperable lung carcinoma after the first chemotherapy a relatively well compatible and effective treatment for the order, which postpones a progressing of the illness still additionally and which number of deaths reduces. That is for these seriously ill people a progress.

Other articles you might like;

• Pharyngeal Cancer
• Tongue Cancer
• Inflammatory Cancer
• Cancer Biomarker
• Cancer Stem Cell

Related posts:

1. Basal Cell Carcinoma
2. Basal Cell Carcinoma
3. Terminal Lung Cancer
4. Sign Of Lung Cancer
5. Metastatic Lung Cancer

You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.